文献速递胃肠外科围术期管理与 ERAS

T1期胃神经内分泌癌转移风险及内镜与手术治疗的生存比较

Risk factors for metastasis and survival of patients with T1 gastric neuroendocrine carcinoma treated with endoscopic therapy versus surgical resection.
PubMed 文献 · Surg Endosc · 2022-05-03

基于SEER数据库205例T1期胃神经内分泌癌患者,研究发现肿瘤>20 mm是转移的最显著危险因素(OR 18.64)。对于黏膜受累且直径≤2 cm的T1N0M0患者,内镜治疗与手术的10年总生存率和癌症特异性生存率无显著差异,提示内镜治疗可能足够。

要点

  • 肿瘤>20 mm是T1期胃神经内分泌癌转移的最显著危险因素。
  • 黏膜受累且肿瘤≤20 mm者未见转移,内镜治疗可能足够。
  • T1N0M0患者内镜治疗与手术的10年生存率无显著差异。

核心结论

  • 肿瘤>20 mm是T1期胃神经内分泌癌转移的最显著危险因素。
  • 对于黏膜受累且肿瘤≤2 cm的T1N0M0患者,内镜治疗可能足够。

研究设计与样本

  • 回顾性队列研究,从SEER数据库收集205例T1期胃神经内分泌癌患者。
  • 采用Logistic回归分析转移的独立预测因素,并计算癌症特异性生存和总生存。

主要发现

  • 黏膜受累且肿瘤≤20 mm者无转移(0%,0/49)。
  • 肿瘤>20 mm的转移风险OR为18.64(95%CI 4.01-86.68,P<0.001)。
  • T1N0M0患者中,黏膜受累组内镜治疗与手术的10年OS分别为91.56%和87.50%(P=0.62),黏膜下受累组分别为57.33%和77.83%(P=0.11)。
  • 10年CSS:黏膜受累组内镜治疗97.30% vs 手术100%(P=0.51),黏膜下组97.62% vs 86.49%(P=0.65)。

关键数值与推荐

  • 肿瘤>20 mm是转移的最显著危险因素(OR 18.64;95%CI 4.01-86.68;P<0.001)。
  • 黏膜受累且肿瘤≤20 mm者未见转移(0%,0/49)。

临床怎么用

  • 对于T1期胃神经内分泌癌,应评估肿瘤大小,>20 mm者转移风险高。
  • 黏膜受累且肿瘤≤2 cm的T1N0M0患者可考虑内镜治疗。
  • 内镜治疗与手术的长期生存相似,但需个体化决策。

局限性

  • 研究为回顾性设计,存在选择偏倚可能。
  • 样本来自SEER数据库,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gastrectomy with lymphadenectomy is recommended for early gastric Neuroendocrine carcinoma (G-NEC). We attempted to determine the prevalence and risk factors of metastasis of T1 G-NEC and compare the long-term survival of patients after receiving endoscopic therapy (ET) and radical surgery. METHODS: In this study, 205 patients in total with T1 G-NEC were collected from the Surveillance Epidemiology and End Result database. Independent predictors of metastasis were identified by Logistic regression analysis, followed by the calculation of both cancer-specific survival (CSS) and overall survival (OS). RESULTS: Twenty-five patients (12.2%) were burdened with metastasis at initial diagnosis, with a prevalence of 5.2% (3/58) in mucosa lesions and 16.2% (16/99) in submucosa lesions (P = 0.045). No metastasis was detected in lesions with mucosa involvement and tumors ≦ 20 mm (0%, 0/49). The most significant risk factor for metastasis was tumors > 20 mm [odds ratio (OR) 18.64; 95% confidence interval (CI) 4.01-86.68; P < 0.001]. For patients with T1N0M0 G-NEC who received ET or surgery, the 10-year OS was similar between the mucosa extension and submucosa extension groups, which was 91.56% in ET group vs 87.50% in surgery group (P = 0.62) and 57.33% vs 77.83% (P = 0.11), respectively. In addition, the 10-year CSS was also similar between the mucosa extension and submucosa extension groups with 97.30% in ET vs 100% in surgery (P = 0.51) and 97.62% vs 86.49% (P = 0.65). CONCLUSIONS: In G-NEC, tumors > 20 mm were considered as the most significant risk factor for metastasis. ET seemed adequate for the lesions with mucosa involvement and size ≦ 2 cm.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Ye H, Yuan Y, Chen P, et al. Risk factors for metastasis and survival of patients with T1 gastric neuroendocrine carcinoma treated with endoscopic therapy versus surgical resection. Surg Endosc. 2022. PMID: 35507062. doi:10.1007/s00464-022-09190-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。